Biofrontera Inc. BFRI 深 沪
已收盘 08-01 16:00:00 美东时间
1.04
-0.040
-3.70%
华盛通- 最 高1.114
- 今 开1.06
- 成交量 7.16万股
- 最 低 1.02
- 昨 收 1.08
- 总市值 982.40万
- 52周最高 2.22
- 市盈率 静 --
- 换手率 0.76%
- 52周最低 0.536
- 委 比 94.62%
- 总股本 944.62万
- 历史最高 292.60
- 量 比 0.74
- 振 幅 8.70%
- 历史最低 0.536
- 每 手 1
- 风险率 0.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biofrontera Finalizes Acquisition of U.S. Ameluz Rights
Biofrontera ( ($BFRI) ) just unveiled an announcement. On June 30, 2025, Biofro...
07-01 21:15
Biofrontera Completes Strategic Restructuring Agreement
An announcement from Biofrontera ( ($DE:B8FK) ) is now available. Biofrontera A...
07-01 07:58
Biofrontera restructures relationship with Biofrontera AG, backed by $11M investment
Biofrontera (NASDAQ:BFRI) said on Monday that it has acquired all U.S. Rights to Ameluz and RhodoLED from its former parent company Biofrontera AG. An $11M investment led by Rosalind Advisors and AIG...
06-30 20:29
Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment
Biofrontera Inc. acquired U.S. rights to Ameluz® and RhodoLED® from Biofrontera AG, reducing royalties to 12% (or 15% above $65 million in revenue). The transaction, supported by an $11 million investment, aims to boost profitability and strengthen its U.S. dermatology market presence.
06-30 12:00
Biofrontera AG Extends Payment Deferral Amid Strategic Negotiations
The latest update is out from Biofrontera ( ($DE:B8FK) ). Biofrontera AG has an...
06-27 02:57
BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG
Biofrontera Inc. confirms negotiations with Biofrontera AG regarding potential company combination or adjustment of their license and supply agreement, which may involve transferring certain rights, obligations, and reducing transfer prices for products sold in the U.S. No definitive terms have been established yet.
06-11 19:00
Biofrontera AG Explores Strategic Changes with Biofrontera Inc.
Biofrontera ( ($DE:B8FK) ) has issued an announcement. Biofrontera AG is curren...
06-10 20:59
Biofrontera AG Pre-announces H1 2025 Financial Report
Biofrontera ( ($DE:B8FK) ) just unveiled an announcement. Biofrontera AG has an...
06-10 20:59
Biofrontera Updates Proxy Statement for 2025 Meeting
The latest update is out from Biofrontera ( ($BFRI) ). On June 3, 2025, Biofron...
06-04 05:55
Biofrontera's Propylene Glycol-Free Ameluz Formulation Receives FDA Orange Book Listing Following April 2025 Patent Approval, Extending Protection Through 2043
Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through to December 2043.The Orange Book is published by the U.S. Food and Drug Administration
06-04 02:34
